Oral PTH Shows Promise for Osteoporosis in Early Phase 2 Study

Marlene Busko | Conference Report | 11 October 2021

An investigational oral form of parathyroid hormone (PTH 1-34), EB 613 (Entera Bio Ltd) met its primary efficacy outcome in a phase 2 dosing study involving postmenopausal women with low bone mineral density (BMD).

The adverse effect profile of the drug was similar to that of the injectable PTH 1-34 ...

Oral PTH Shows Promise for Osteoporosis in Early Phase 2 Study

December Challenge

Does the Mediterranean diet have protective effects on adverse pregnancy outcomes?

What is the most effective digitally assisted intervention to reduce glycated haemoglobin?

How effective is endoscopic screening in reducing the risk for gastric cancer mortality?

What is the association between apolipoproteins and metabolic syndrome?

Can tumour-infiltrating lymphocyte scores affect treatment decisions?

Do different exercise training modes have different effects on resting blood pressure?

How are neurocutaneous syndromes associated with central nervous system tumours in childhood?

Topic Challenges

Quiz challenge Emerging diseases: COVID-19

ESMO 2020 topic challenge

Women's health challenge

Antibiotics - Consequence of MDR carriage

Neurological disorders challenge

Rheumatology challenge

Lyme Disease

Mental health challenge

Topic challenge - Children conditions

Lyme Disease